Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
NCT ID: NCT02225470
Last Updated: 2018-08-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
530 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-09-26
Study Completion Date
2018-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is designed as an open-label randomized parallel two-arm multicenter efficacy, pharmacokinetics and safety study of intravenously administered eribulin versus intravenously administered vinorelbine in Chinese population. Eligible female subjects will have measurable disease according to RECIST 1.1 with the modification that chest x-ray cannot be used for assessment of disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
NCT05402722
TNBC - Triple-Negative Breast Cancer
UNKNOWN
PHASE2
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
NCT02513472
Breast Neoplasm
COMPLETED
PHASE1/PHASE2
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
NCT05206656
Metastatic Breast Cancer
COMPLETED
PHASE2
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
NCT06857305
Breast Cancer Metastatic
ENROLLING_BY_INVITATION
PHASE3
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
NCT02030678
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HER2-Negative Breast Cancer
Triple Negative Breast Cancer
Breast Cancer
Cancer of Breast
Breast Tumors
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A, E7389 (Eribulin Mesylate)
The eribulin mesylate dose will be 1.4 mg/m2 administered as an intravenous bolus over 2 to 5 minutes on Days 1 and 8 of each 21-day cycle.
Group Type
EXPERIMENTAL
E7389 (Eribulin Mesylate)
Intervention Type
DRUG
Arm B, Vinorelbine injection
The vinorelbine dose will be 25 mg/m2 administered as an intravenous bolus on Days 1, 8, and 15 of each 21-day treatment cycle.
Group Type
ACTIVE_COMPARATOR
Vinorelbine injection
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E7389 (Eribulin Mesylate)
Intervention Type
DRUG
Vinorelbine injection
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Subjects must meet all of the following criteria to be included in this study.
1. Female subjects with histologically or cytologically confirmed carcinoma of the breast:
2. Subjects with locally recurrent or metastatic disease who have received at least two, and a maximum of five, prior chemotherapeutic regimens for breast cancer, at least two of which were administered for treatment of locally recurrent or metastatic disease. Prior therapy must be documented by the following criteria prior to entry onto study:
1. Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin), and a taxane (e.g., paclitaxel, docetaxel) in any combination or order. Prior treatment with any of these agents is not required if the agents are contraindicated for a prospective subject and documented in her medical history.
2. Some of these regimens may have been administered as adjuvant and/or neoadjuvant therapy, but at least two must have been given for locally recurrent or metastatic disease.
3. Subjects must have proven refractory to the most recent chemotherapy as documented by progression on or within 6 months of their last chemotherapy.
4. Subjects with Her2/neu positive tumors may also have been treated with any Her2/neu targeted agents including antibodies, small compounds or investigational drugs.
5. Subjects may also have been treated with antihormonal therapy.
3. Have measurable disease meeting the following criteria:
1. At least one lesion of greater than or equal to 1.0 cm in the longest diameter for a non-lymph node, or greater than or equal to 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of greater than or equal to 1.5 cm.
2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based upon RECIST 1.1 to be used as a target lesion.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
5. Life expectancy of greater than or equal to 3 months.
6. subjects greater than or equal to 18 years old Age and less than or equal to 70 years old at the time of informed consent.
7. Adequate renal function as evidenced by serum creatinine less than or equal to 2.0 mg/dL or calculated creatinine clearance greater than or equal to 40 mL/min per the Cockcroft and Gault formula.
8. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\^9/L, hemoglobin greater than or equal to 10.0 g/dL, and platelet count greater than or equal to 100 x 10\^9/L.
9. Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limits of normal (ULN); and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3.0 times ULN (in the case of liver metastases less than or equal to 5.0 times ULN).
10. Subject willing and able to comply with the study protocol for the duration of the study.
11. All female subjects will be considered to be of child-bearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically (i.e., bilateral tubal ligation greater than or equal to 1 menstrual cycle prior to randomization, or have undergone a hysterectomy and/or bilateral oophorectomy).
Female subjects of child-bearing potential must agree to use two forms of highly effective contraception from the last menstrual period prior to randomization (or use a double barrier method as described below until they are on two forms of highly effective contraception for at least one menstrual cycle), during study treatment, and for 3 months after the final dose of study treatment. Female subjects exempt from this requirement are subjects who practice total abstinence. If currently abstinent, the subject must agree to use a double barrier method of contraception, i.e. condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide or until they are on two forms of highly effective contraception for at least one menstrual cycle if they become sexually active during study treatment and for 3 months after the final dose of study treatment. Highly effective contraception includes:
1. Placement of intrauterine device or system,
2. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault cap) with spermicide,
3. Established hormonal contraceptive methods: oral, injectable or implant. Female subjects who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product from the last menstrual period prior to randomization, and must continue to use the same hormonal contraceptive product during study treatment, and for 3 months after the final dose of study treatment,
4. Vasectomized partner with confirmed azoospermia.
12. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol, with the understanding that the patient may withdraw consent at any time without prejudice.
1. Female subjects with histologically or cytologically confirmed carcinoma of the breast:
2. Subjects with locally recurrent or metastatic disease who have received at least two, and a maximum of five, prior chemotherapeutic regimens for breast cancer, at least two of which were administered for treatment of locally recurrent or metastatic disease. Prior therapy must be documented by the following criteria prior to entry onto study:
1. Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin), and a taxane (e.g., paclitaxel, docetaxel) in any combination or order. Prior treatment with any of these agents is not required if the agents are contraindicated for a prospective subject and documented in her medical history.
2. Some of these regimens may have been administered as adjuvant and/or neoadjuvant therapy, but at least two must have been given for locally recurrent or metastatic disease.
3. Subjects must have proven refractory to the most recent chemotherapy as documented by progression on or within 6 months of their last chemotherapy.
4. Subjects with Her2/neu positive tumors may also have been treated with any Her2/neu targeted agents including antibodies, small compounds or investigational drugs.
5. Subjects may also have been treated with antihormonal therapy.
3. Have measurable disease meeting the following criteria:
1. At least one lesion of greater than or equal to 1.0 cm in the longest diameter for a non-lymph node, or greater than or equal to 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of greater than or equal to 1.5 cm.
2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based upon RECIST 1.1 to be used as a target lesion.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
5. Life expectancy of greater than or equal to 3 months.
6. subjects greater than or equal to 18 years old Age and less than or equal to 70 years old at the time of informed consent.
7. Adequate renal function as evidenced by serum creatinine less than or equal to 2.0 mg/dL or calculated creatinine clearance greater than or equal to 40 mL/min per the Cockcroft and Gault formula.
8. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\^9/L, hemoglobin greater than or equal to 10.0 g/dL, and platelet count greater than or equal to 100 x 10\^9/L.
9. Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limits of normal (ULN); and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3.0 times ULN (in the case of liver metastases less than or equal to 5.0 times ULN).
10. Subject willing and able to comply with the study protocol for the duration of the study.
11. All female subjects will be considered to be of child-bearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically (i.e., bilateral tubal ligation greater than or equal to 1 menstrual cycle prior to randomization, or have undergone a hysterectomy and/or bilateral oophorectomy).
Female subjects of child-bearing potential must agree to use two forms of highly effective contraception from the last menstrual period prior to randomization (or use a double barrier method as described below until they are on two forms of highly effective contraception for at least one menstrual cycle), during study treatment, and for 3 months after the final dose of study treatment. Female subjects exempt from this requirement are subjects who practice total abstinence. If currently abstinent, the subject must agree to use a double barrier method of contraception, i.e. condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide or until they are on two forms of highly effective contraception for at least one menstrual cycle if they become sexually active during study treatment and for 3 months after the final dose of study treatment. Highly effective contraception includes:
1. Placement of intrauterine device or system,
2. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault cap) with spermicide,
3. Established hormonal contraceptive methods: oral, injectable or implant. Female subjects who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product from the last menstrual period prior to randomization, and must continue to use the same hormonal contraceptive product during study treatment, and for 3 months after the final dose of study treatment,
4. Vasectomized partner with confirmed azoospermia.
12. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol, with the understanding that the patient may withdraw consent at any time without prejudice.
Exclusion Criteria
Subjects who meet any of the following criteria will be excluded from this study:
1. Subjects who have received any of the following treatments within the specified period before treatment start:
1. Vinorelbine has been administrated as neoadjuvant or adjuvant therapy within one year.
2. Chemotherapy, radiation, Her2/neu targeted agents including trastuzumab or hormonal therapy within three weeks.
3. Any investigational drug within four weeks.
4. Blood transfusion, blood preparations and hematopoietic factor preparations such as G-CSF within two weeks.
2. Subjects of advanced breast cancer with vinorelbine effective therapy to CR/PR/SD, and PD occurred after vinorelbine discontinuing within 6 months.
3. Subjects with ineffective prior vinorelbine treatment.
4. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
5. Subjects with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least four weeks before starting treatment in this study. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least four weeks before starting study treatment; and radiographic stability should be determined by comparing a contrast-enhanced CT or MRI brain scan performed during screening to a prior scan performed at least four weeks earlier.
6. Subjects with meningeal carcinomatosis.
7. Woman must not be pregnant as documented by a negative beta-human chorionic gonadotropin (beta-hCG) test with a minimum sensitivity 25 IU/L, or equivalent unit of beta-hCG, at Screening and Baseline; nor breastfeeding.
8. Severe/uncontrolled intercurrent illness/infection.
9. Significant cardiovascular impairment (history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).
10. Subjects with organ allografts requiring immunosuppression therapy.
11. Subjects with known positive HIV status.
12. Subjects who have had a prior malignancy, other than breast cancer, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated at least five years previously with no subsequent evidence of recurrence.
13. Subjects with preexisting neuropathy greater than Grade 2.
14. Subjects with a hypersensitivity to halichondrin B and/or a halichondrin B chemical derivative.
15. Subjects who participated in a prior eribulin clinical trial whether or not eribulin was received.
16. Known intolerance to eribulin or vinorelbine (or any of the excipients).
17. Any medical condition that in the investigator's opinion may preclude subject from being entered in the study.
1. Subjects who have received any of the following treatments within the specified period before treatment start:
1. Vinorelbine has been administrated as neoadjuvant or adjuvant therapy within one year.
2. Chemotherapy, radiation, Her2/neu targeted agents including trastuzumab or hormonal therapy within three weeks.
3. Any investigational drug within four weeks.
4. Blood transfusion, blood preparations and hematopoietic factor preparations such as G-CSF within two weeks.
2. Subjects of advanced breast cancer with vinorelbine effective therapy to CR/PR/SD, and PD occurred after vinorelbine discontinuing within 6 months.
3. Subjects with ineffective prior vinorelbine treatment.
4. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.
5. Subjects with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least four weeks before starting treatment in this study. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least four weeks before starting study treatment; and radiographic stability should be determined by comparing a contrast-enhanced CT or MRI brain scan performed during screening to a prior scan performed at least four weeks earlier.
6. Subjects with meningeal carcinomatosis.
7. Woman must not be pregnant as documented by a negative beta-human chorionic gonadotropin (beta-hCG) test with a minimum sensitivity 25 IU/L, or equivalent unit of beta-hCG, at Screening and Baseline; nor breastfeeding.
8. Severe/uncontrolled intercurrent illness/infection.
9. Significant cardiovascular impairment (history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).
10. Subjects with organ allografts requiring immunosuppression therapy.
11. Subjects with known positive HIV status.
12. Subjects who have had a prior malignancy, other than breast cancer, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated at least five years previously with no subsequent evidence of recurrence.
13. Subjects with preexisting neuropathy greater than Grade 2.
14. Subjects with a hypersensitivity to halichondrin B and/or a halichondrin B chemical derivative.
15. Subjects who participated in a prior eribulin clinical trial whether or not eribulin was received.
16. Known intolerance to eribulin or vinorelbine (or any of the excipients).
17. Any medical condition that in the investigator's opinion may preclude subject from being entered in the study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Co., Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
04 Eisai Trial Site
Bengbu, Anhui, China
Site Status
37 Eisai Trial Site
Hefei, Anhui, China
Site Status
01 Eisai Trial Site
Beijing, Beijing Municipality, China
Site Status
03 Eisai Trial Site
Beijing, Beijing Municipality, China
Site Status
33 Eisai Trial Site
Beijing, Beijing Municipality, China
Site Status
35 Eisai Trial Site
Beijing, Beijing Municipality, China
Site Status
07 Eisai Trial Site
Fuzhou, Fujian, China
Site Status
08 Eisai Trial Site
Fuzhou, Fujian, China
Site Status
20 Eisai Trial Site
Guangzhou, Guangdong, China
Site Status
36 Eisai Trial Site
Guangzhou, Guangdong, China
Site Status
10 Eisai Trial Site
Nanning, Guangxi, China
Site Status
12 Eisai Trial Site
Shijiazhuang, Hebei, China
Site Status
11 Eisai Trial Site
Harbin, Heilongjiang, China
Site Status
38 Eisai Trial Site
Zhengzhou, Henan, China
Site Status
14 Eisai Trial Site
Wuhan, Hubei, China
Site Status
15 Eisai Trial Site
Wuhan, Hubei, China
Site Status
05 Eisai Trial Site
Changsha, Hunan, China
Site Status
13 Eisai Trial Site
Changsha, Hunan, China
Site Status
34 Eisai Trial Site
Changsha, Hunan, China
Site Status
18 Eisai Trial Site
Nanjing, Jiangsu, China
Site Status
31 Eisai Trial Site
Nanjing, Jiangsu, China
Site Status
16 Eisai Trial Site
Changchun, Jilin, China
Site Status
17 Eisai Trial Site
Changchun, Jilin, China
Site Status
06 Eisai Trial Site
Dalian, Liaoning, China
Site Status
19 Eisai Trial Site
Shenyang, Liaoning, China
Site Status
21 Eisai Trial Site
Yinchuang, Ningxia, China
Site Status
24 Eisai Trial Site
Xi'an, Shaanxi, China
Site Status
28 Eisai Trial Site
Xi'an, Shaanxi, China
Site Status
22 Eisai Trial Site
Qingdao, Shandong, China
Site Status
09 Eisai Trial Site
Shanghai, Shanghai Municipality, China
Site Status
23 Eisai Trial Site
Taiyuan, Shanxi, China
Site Status
26 Eisai Trial Site
Chengtu, Sichuan, China
Site Status
27 Eisai Trial Site
Tianjin, Tianjin Municipality, China
Site Status
30 Eisai Trial Site
Yunnan, Yunnan, China
Site Status
40 Eisai Trial Site
Hangzhou, Zhejiang, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
References
Explore related publications, articles, or registry entries linked to this study.
Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, Cheng Y, Ouyang Q, Wang X, Chen Z, Hiraiwa M, Saito K, Funasaka S, Xu B. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer. 2019 May;112:57-65. doi: 10.1016/j.ejca.2019.02.002. Epub 2019 Mar 29.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E7389-C086-304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
NCT06308939
NOT_YET_RECRUITING
PHASE2
Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
NCT05546255
UNKNOWN
PHASE2
Study of E7389 for Advanced or Metastatic Breast Cancer
NCT00965523
COMPLETED
PHASE2
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
NCT07255612
NOT_YET_RECRUITING
PHASE2
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
NCT02061085
COMPLETED
PHASE2
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients
NCT04502680
UNKNOWN
PHASE2
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
NCT01268150
COMPLETED
PHASE2
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
NCT02481050
COMPLETED
PHASE2
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
NCT05945368
UNKNOWN
PHASE2
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
NCT00337103
COMPLETED
PHASE3
Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients
NCT03795012
TERMINATED
PHASE2
Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer
NCT05263882
UNKNOWN
PHASE2
Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles
NCT06868017
NOT_YET_RECRUITING
PHASE4
A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).
NCT05953909
UNKNOWN
Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
NCT04517292
UNKNOWN
PHASE2
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
NCT04683445
UNKNOWN
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
NCT05530057
RECRUITING
PHASE2
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
NCT02120469
COMPLETED
PHASE1
Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
NCT01961544
COMPLETED
PHASE4
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
NCT06202261
RECRUITING
PHASE1/PHASE2
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
NCT05302778
UNKNOWN
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
NCT06678230
NOT_YET_RECRUITING
PHASE2
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
NCT01401959
COMPLETED
PHASE2
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
NCT06081959
RECRUITING
PHASE3
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
NCT04624711
UNKNOWN
PHASE2